Both Vericel Corporation (NASDAQ:VCEL) and BioTime Inc. (:) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

We can see in table 1 the earnings per share, gross revenue and valuation of Vericel Corporation and BioTime Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

Volatility and Risk

Vericel Corporation has a 2.72 beta, while its volatility is 172.00% which is more volatile than S&P 500. BioTime Inc. has a 2.81 beta and it is 181.00% more volatile than S&P 500.

Liquidity

Vericel Corporations Current Ratio is 8.5 while its Quick Ratio is 8.2. On the competitive side is, BioTime Inc. which has a 3.5 Current Ratio and a 3.5 Quick Ratio. Vericel Corporation is better positioned to pay off short and long-term obligations compared to BioTime Inc.

Analyst Recommendations

The Recommendations and Ratings for Vericel Corporation and BioTime Inc. are featured in the next table.

Vericel Corporations upside potential currently stands at 48.79% and an $21.5 average price target.

Institutional and Insider Ownership

The shares of both Vericel Corporation and BioTime Inc. are owned by institutional investors at 89% and 43.7% respectively. About 0.5% of Vericel Corporations share are held by insiders. Insiders Comparatively, held 3.9% of BioTime Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Vericel Corporations stock price has smaller growth than BioTime Inc.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the article here:
Vericel Corporation (VCEL) and BioTime Inc. (:) Contrasting side by side - MS Wkly